Investors looking for a respite from the ongoing market volatility may want to seek out dividend-paying stocks. The benefit of these stocks is that they give you an opportunity for reliable income today and into the future. Many of these stocks have fallen out of fashion in the tech-fueled AI revolution. But in the last month, many of these stocks are increasing as investors feel more bullish about the economy.  Investors who reinvest those dividends have the opportunity to increase their total return on th ...

Everything looked like it was coming undone last week. As recession fears gripped the market, the S&P 500 tumbled 3% in a single day. The Nasdaq 100 lost more than 1,000 points at one point, its worst loss ever, before regaining some of the lost ground.Although the situation turned markedly better by Tuesday and continued improving as the week progressed, the whipsaw event still has investors cautious. Wild swing trades can often signal a new, worse crash is coming. That’s why it’s important to prepare for ...

All of these stocks can provide steady income to retired investors.Many retirees are investors for a good reason: They can't rely entirely on Social Security to fund their retirement. Investing wisely provides a means to retire comfortably.Three Motley Fool contributors think they have found stocks to buy that retirees should absolutely love. All three offer juicy dividend yields. Here are their cases for AbbVie (ABBV -0.25%), Bristol Myers Squibb (BMY -0.28%), and Gilead Sciences (GILD -2.55%). Everything ...

Eric Francis Only when the tide goes out do you discover who's been swimming naked. - Warren Buffett Written by Sam Kovacs Introduction Every day, 10,000 Baby Boomers reach retirement age. This means that in July, as many as 300,000 Americans could have retired. Many of those have had a timing issue with retiring, depending on how they invested their savings, and I'm going to demonstrate this in this article. I'll also show you how all of this trouble could have been avoided by building what we like to ...

Financial Performance - Worldwide net revenues for the six months ended June 30, 2024 were $26.8 billion, a 3% increase on a reported basis and 4% on a constant currency basis[131] - Diluted earnings per share for the six months ended June 30, 2024 was $1.53, including $3.3 billion related to the amortization of intangible assets and $2.1 billion for the change in fair value of contingent consideration liabilities[131] - Gross margin as a percentage of net revenues increased to 71% for the three months and 69% for the six months ended June 30, 2024, due to lower amortization of intangibles[151] - R&D expenses increased to $1,948 million for the three months ended June 30, 2024, up 12% from $1,733 million in the prior year[154] - R&D expenses as a percentage of net revenues increased to 13% for the three months ended June 30, 2024, compared to 12% in the prior year[154] - Interest expense increased to $726 million for the three months ended June 30, 2024, up from $552 million in the prior year, primarily due to financing acquisitions[156] - Interest income increased to $220 million for the three months ended June 30, 2024, up from $98 million in the prior year, driven by higher cash balances and interest rates[157] - Other expense, net included $1.5 billion in charges related to changes in fair value of contingent consideration liabilities for the three months ended June 30, 2024[158] - The effective tax rate increased to 36% for the three months ended June 30, 2024, compared to 22% in the prior year, primarily due to business development activities[159] - Operating cash flows decreased to $6,311 million for the six months ended June 30, 2024, down from $10,512 million in the prior year, due to higher contingent consideration payments[160] - Investing cash flows for the six months ended June 30, 2024 included $9.8 billion cash consideration paid to acquire ImmunoGen[161] - Financing cash flows for the six months ended June 30, 2024 included the issuance of $15.0 billion in senior notes to finance acquisitions[162] Product Revenue Performance - Humira's total revenue decreased by 29.8% to $2.814 billion in the three months ended June 2024 compared to the same period in 2023[144] - Skyrizi's total revenue increased by 44.8% to $2.727 billion in the three months ended June 2024 compared to the same period in 2023[144] - Rinvoq's total revenue increased by 55.8% to $1.430 billion in the three months ended June 2024 compared to the same period in 2023[144] - Imbruvica's total revenue decreased by 8.2% to $833 million in the three months ended June 2024 compared to the same period in 2023[144] - Venclexta's total revenue increased by 11.5% to $637 million in the three months ended June 2024 compared to the same period in 2023[144] - Botox Cosmetic's total revenue increased by 6.4% to $729 million in the three months ended June 2024 compared to the same period in 2023[144] - Vraylar's total revenue increased by 17.6% to $774 million in the three months ended June 2024 compared to the same period in 2023[144] - Ubrelvy's total revenue increased by 17.5% to $231 million in the three months ended June 2024 compared to the same period in 2023[144] - Qulipta's total revenue increased by 56.3% to $150 million in the three months ended June 2024 compared to the same period in 2023[144] - Epkinly's total revenue increased by over 100% to $36 million in the three months ended June 2024 compared to the same period in 2023[144] - Global Humira sales decreased by 29% for the three months and 32% for the six months ended June 30, 2024, driven by biosimilar competition[146] - Skyrizi net revenues increased by 46% for the three months and 47% for the six months ended June 30, 2024, driven by strong market share uptake[146] - Rinvoq net revenues increased by 59% for the three months and 60% for the six months ended June 30, 2024, driven by market growth[147] - Imbruvica global revenues decreased by 8% for the three months and 6% for the six months ended June 30, 2024, due to decreased demand in the U.S.[147] - Venclexta net revenues increased by 16% for the three and six months ended June 30, 2024, driven by market share uptake[147] - Elahere net revenues were $128 million for the three months and $192 million for the six months ended June 30, 2024, following the ImmunoGen acquisition[148] - Botox Cosmetic net revenues increased by 9% for the three months and 3% for the six months ended June 30, 2024, driven by favorable pricing[148] - Vraylar net revenues increased by 18% for the three months and 20% for the six months ended June 30, 2024, driven by market share uptake[150] - Qulipta net revenues increased by 56% for the three months and 73% for the six months ended June 30, 2024, driven by strong market share uptake[150] Pipeline and Product Development - AbbVie completed the acquisition of ImmunoGen, Inc. on February 12, 2024, enhancing its solid tumor pipeline and antibody-drug conjugate (ADC) therapies[128] - AbbVie's pipeline includes approximately 90 compounds, devices, or indications in development, with about 50 in mid- and late-stage development[133] - Rinvoq achieved positive top-line results in Phase 3 trials for giant cell arteritis (GCA) and atopic dermatitis, and received FDA approval for pediatric polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA)[135] - Skyrizi received FDA and European Commission approvals for the treatment of moderately to severely active ulcerative colitis (UC)[136] - Epkinly received FDA approval for relapsed or refractory follicular lymphoma (FL) and a positive opinion from the EMA Committee for Medicinal Products for Human Use[138] - Elahere received full FDA approval for FRα-positive, platinum-resistant epithelial ovarian cancer and positive Phase 2 results for platinum-sensitive ovarian cancer[139] - AbbVie initiated a Phase 3 clinical trial for ABBV-383 in relapsed or refractory multiple myeloma[139] - ABBV-951 received a Complete Response Letter (CRL) from the FDA for the treatment of motor fluctuations in advanced Parkinson's disease, citing issues with a third-party manufacturer[141] - Acquired IPR&D and milestones expense for the three months ended June 30, 2024 included a $250 million upfront payment for Celsius Therapeutics[155]

Recent market pressure could worsen, but that won't stop these successful businesses from raising their dividend payouts.If you're more nervous than usual about buying stocks these days you're not alone. From July 16 through Aug. 2, the benchmark S&P 500 index fell about 5.7% from its all-time high.The recent stock market drop is still a few points shy of an official market correction, but it's enough to make everyday investors think twice before purchasing risky growth stocks.If fear of a market correction ...

GeorgePeters Introduction Things aren't going so well anymore. The AI-fueled tech rally has stalled, and all eyes are now on the "real" economy, which is showing some serious cracks. The just-released unemployment numbers, for example, came in much lower than expected, with nonfarm payrolls indicating just 114 thousand new jobs in July. The prior month's gain was revised from 206 thousand to 179 thousand. The unemployment rate rose to 4.3%, 20 basis points higher than expected. Bloomberg These numbers c ...

On Jul 25, AbbVie (ABBV) announced strong second-quarter results. AbbVie beat estimates for both earnings and sales. Earnings declined 8.9% year over year due to costs related to recent acquisitions and deals. Sales rose 5.6% year over year on an operational basis.AbbVie lost patent protection for its blockbuster immunology drug Humira in the United States in January 2023 and in the EU in 2018. Sales of Humira are declining due to loss of exclusivity and biosimilar erosion. However, in the second quarter, s ...

Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's diseaseEmraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophreniaCerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decadeAbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.9 ...

patpitchaya/iStock via Getty Images Introduction When investing one should always have a long-term outlook. Day or short-term trading can give you potential gains, but this will likely end badly if you continue with this strategy. To me, this is similar to going to a casino and hitting a few winning hands on the blackjack table. Question always is: "How long will this last?" No one knows, but it surely won't last forever. That's why you should play the long game, especially when investing in stocks that ...